Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasms, Hormone-Dependent 2Carcinoma, Lobular 2Carcinoma, Ductal, Breast 2Breast Neoplasms 2

Interventions

Letrozole 6Radiotherapy 4Carboplatin 4atamestane 3Trastuzumab 3Toremifene 3Magnetic Resonance Spectroscopy 3Fulvestrant 3Docetaxel 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Tamoxifen 2Paclitaxel 2Estrogen Receptor Modulators 2Capecitabine 2Aromatase Inhibitors 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1gallium 68 PSMA-11 1fluciclovine F-18 1entrectinib 1Zolpidem 1Vorinostat 1Vinorelbine 1Venlafaxine Hydrochloride 1Thiotepa 1Taxes 1Sugars 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Lobular × Estrogen Receptor Modulators × Clear all
NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Completed
865 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
842 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡